Speaker Profile

___	__
	Biography Dr. Ziegler is an Obstetrician Gynecologist in practice at the Jewish General Hospital in Montreal since 1994 and is Assistant Professor of Obstetrics and Gynecology at McGill University. His fellowship training was in Gynecological Surgery at the Cleveland Clinic. Clinical interests include complex and minimally invasive gynecological surgery, colposcopy, contraception and menopause. He has been continuously involved in resident training and continuing medical education for family physicians and specialists. He is an examiner for the Royal College and is on the editorial board of the JOGC journal. He is most famous for a UFO sighting and will be happy to share that story if you buy him a drink. Disclosure I have a relationship with a for-profit and/or a not-for-profit organization to disclose: - Membership on advisory boards or speakers’ bureaus: Abbvie, Biosyent, Organon, Pfizer I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).

Biography
Dr. Ziegler is an Obstetrician Gynecologist in practice at the Jewish General Hospital in Montreal since 1994 and is Assistant Professor of Obstetrics and Gynecology at McGill University. His fellowship training was in Gynecological Surgery at the Cleveland Clinic. Clinical interests include complex and minimally invasive gynecological surgery, colposcopy, contraception and menopause. He has been continuously involved in resident training and continuing medical education for family physicians and specialists. He is an examiner for the Royal College and is on the editorial board of the JOGC journal. He is most famous for a UFO sighting and will be happy to share that story if you buy him a drink.
Disclosure
I have a relationship with a for-profit and/or a not-for-profit organization to disclose: - Membership on advisory boards or speakers’ bureaus: Abbvie, Biosyent, Organon, Pfizer I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).